328 related articles for article (PubMed ID: 27567857)
1. Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases.
Binukumar BK; Pelech SL; Sutter C; Shukla V; Amin ND; Grant P; Bhaskar M; Skuntz S; Steiner J; Pant HC
J Alzheimers Dis; 2016 Sep; 54(2):525-33. PubMed ID: 27567857
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.
Binukumar BK; Shukla V; Amin ND; Bhaskar M; Skuntz S; Steiner J; Winkler D; Pelech SL; Pant HC
J Alzheimers Dis; 2015; 48(4):1009-17. PubMed ID: 26444778
[TBL] [Abstract][Full Text] [Related]
3. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.
Zheng YL; Li BS; Amin ND; Albers W; Pant HC
Eur J Biochem; 2002 Sep; 269(18):4427-34. PubMed ID: 12230554
[TBL] [Abstract][Full Text] [Related]
4. A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.
Zheng YL; Amin ND; Hu YF; Rudrabhatla P; Shukla V; Kanungo J; Kesavapany S; Grant P; Albers W; Pant HC
J Biol Chem; 2010 Oct; 285(44):34202-12. PubMed ID: 20720012
[TBL] [Abstract][Full Text] [Related]
5. The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35.
Amin ND; Zheng Y; Bk B; Shukla V; Skuntz S; Grant P; Steiner J; Bhaskar M; Pant HC
Mol Biol Cell; 2016 Nov; 27(21):3221-3232. PubMed ID: 27630261
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats.
Tan X; Chen Y; Li J; Li X; Miao Z; Xin N; Zhu J; Ge W; Feng Y; Xu X
Neuroscience; 2015 Apr; 290():552-60. PubMed ID: 25665755
[TBL] [Abstract][Full Text] [Related]
7. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
Kesavapany S; Zheng YL; Amin N; Pant HC
Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
[TBL] [Abstract][Full Text] [Related]
8. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
Hisanaga S; Saito T
Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
[TBL] [Abstract][Full Text] [Related]
9. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons.
Zheng YL; Kesavapany S; Gravell M; Hamilton RS; Schubert M; Amin N; Albers W; Grant P; Pant HC
EMBO J; 2005 Jan; 24(1):209-20. PubMed ID: 15592431
[TBL] [Abstract][Full Text] [Related]
10. Computational study of the inhibitory mechanism of the kinase CDK5 hyperactivity by peptide p5 and derivation of a pharmacophore.
Cardone A; Brady M; Sriram R; Pant HC; Hassan SA
J Comput Aided Mol Des; 2016 Jun; 30(6):513-21. PubMed ID: 27387995
[TBL] [Abstract][Full Text] [Related]
11. Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells.
Ubeda M; Kemp DM; Habener JF
Endocrinology; 2004 Jun; 145(6):3023-31. PubMed ID: 14976144
[TBL] [Abstract][Full Text] [Related]
12. Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation.
Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
Biochem Biophys Res Commun; 2002 Nov; 298(5):693-8. PubMed ID: 12419309
[TBL] [Abstract][Full Text] [Related]
13. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.
Sun LH; Ban T; Liu CD; Chen QX; Wang X; Yan ML; Hu XL; Su XL; Bao YN; Sun LL; Zhao LJ; Pei SC; Jiang XM; Zong DK; Ai J
J Neurochem; 2015 Sep; 134(6):1139-51. PubMed ID: 26118667
[TBL] [Abstract][Full Text] [Related]
14. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro.
Town T; Zolton J; Shaffner R; Schnell B; Crescentini R; Wu Y; Zeng J; DelleDonne A; Obregon D; Tan J; Mullan M
J Neurosci Res; 2002 Aug; 69(3):362-72. PubMed ID: 12125077
[TBL] [Abstract][Full Text] [Related]
15. Transient enhanced expression of Cdk5 activator p25 after acute and chronic d-amphetamine administration.
Mlewski EC; Krapacher FA; Ferreras S; Paglini G
Ann N Y Acad Sci; 2008 Oct; 1139():89-102. PubMed ID: 18991853
[TBL] [Abstract][Full Text] [Related]
16. A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves neurodegenerative phenotypes.
Pao PC; Seo J; Lee A; Kritskiy O; Patnaik D; Penney J; Raju RM; Geigenmuller U; Silva MC; Lucente DE; Gusella JF; Dickerson BC; Loon A; Yu MX; Bula M; Yu M; Haggarty SJ; Tsai LH
Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2217864120. PubMed ID: 37043533
[TBL] [Abstract][Full Text] [Related]
17. Partial rescue of the p35-/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene.
Patzke H; Maddineni U; Ayala R; Morabito M; Volker J; Dikkes P; Ahlijanian MK; Tsai LH
J Neurosci; 2003 Apr; 23(7):2769-78. PubMed ID: 12684463
[TBL] [Abstract][Full Text] [Related]
18. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology.
Maccioni RB; Otth C; Concha II; Muñoz JP
Eur J Biochem; 2001 Mar; 268(6):1518-27. PubMed ID: 11248668
[TBL] [Abstract][Full Text] [Related]
19. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
[TBL] [Abstract][Full Text] [Related]
20. CDK5 activator protein p25 preferentially binds and activates GSK3β.
Chow HM; Guo D; Zhou JC; Zhang GY; Li HF; Herrup K; Zhang J
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4887-95. PubMed ID: 25331900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
